We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Aveanna Healthcare (AVAH - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Aveanna Healthcare is a member of the Medical sector. This group includes 915 individual stocks and currently holds a Zacks Sector Rank of #10. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Aveanna Healthcare is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AVAH's full-year earnings has moved 23.2% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AVAH has returned about 56.4% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 2.8% on a year-to-date basis. This means that Aveanna Healthcare is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Charles River Laboratories (CRL - Free Report) . The stock is up 48.4% year-to-date.
In Charles River Laboratories' case, the consensus EPS estimate for the current year increased 3.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Aveanna Healthcare belongs to the Medical - Outpatient and Home Healthcare industry, which includes 14 individual stocks and currently sits at #55 in the Zacks Industry Rank. Stocks in this group have gained about 19.3% so far this year, so AVAH is performing better this group in terms of year-to-date returns.
Charles River Laboratories, however, belongs to the Medical Services industry. Currently, this 72-stock industry is ranked #101. The industry has moved +4.4% so far this year.
Aveanna Healthcare and Charles River Laboratories could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
View the Zacks #1 Rank List
Image: Bigstock
Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Aveanna Healthcare (AVAH - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Aveanna Healthcare is a member of the Medical sector. This group includes 915 individual stocks and currently holds a Zacks Sector Rank of #10. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Aveanna Healthcare is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AVAH's full-year earnings has moved 23.2% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AVAH has returned about 56.4% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 2.8% on a year-to-date basis. This means that Aveanna Healthcare is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Charles River Laboratories (CRL - Free Report) . The stock is up 48.4% year-to-date.
In Charles River Laboratories' case, the consensus EPS estimate for the current year increased 3.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Aveanna Healthcare belongs to the Medical - Outpatient and Home Healthcare industry, which includes 14 individual stocks and currently sits at #55 in the Zacks Industry Rank. Stocks in this group have gained about 19.3% so far this year, so AVAH is performing better this group in terms of year-to-date returns.
Charles River Laboratories, however, belongs to the Medical Services industry. Currently, this 72-stock industry is ranked #101. The industry has moved +4.4% so far this year.
Aveanna Healthcare and Charles River Laboratories could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.